Loomis, Sayles & Company
LRMR icon

Loomis, Sayles & Company’s Larimar Therapeutics LRMR Stock Holding History

Loomis, Sayles & Company’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-34,322
Closed -$13.2M – 1087
2015
Q3 		$13.2M Sell
34,322
-35
-0.1% -$15.8K 0.04% 379
2015
Q2 		$14.3M Buy
34,357
+7,254
+27% +$3.03M 0.04% 414
2015
Q1 		$12.9M Buy
+27,103
New +$12.9M 0.04% 446

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Loomis, Sayles & Company's LRMR Position: Q4 2015 in Review

Loomis, Sayles & Company sold out of Larimar Therapeutics (LRMR) in Q4 2015, closing a stake of 34,322 shares — an estimated $13.2M sold.

Loomis, Sayles & Company first reported a position in LRMR in Q1 2015 and held it in 3 quarters. The position peaked at $14.3M in Q2 2015. 87 funds tracked by Wall St. Rank hold LRMR as of Q4 2015.

  • Loomis, Sayles & Company reported no remaining Larimar Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Loomis, Sayles & Company sold 34,322 Larimar Therapeutics shares in Q4 2015, an estimated $13.2M.
  • Loomis, Sayles & Company first reported a position in Larimar Therapeutics in Q1 2015 and held it in 3 quarters.
  • Loomis, Sayles & Company's Larimar Therapeutics position peaked at $14.3M in Q2 2015.
  • 87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2015.

Based on Loomis, Sayles & Company's 13F filing for Q4 2015, filed 12 Feb 2016.